Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25366648 | 0.98 | CA2 (0.45) | CA2CA9ALDH1A1GAAHTT | |
| SCHEMBL5028293 | 0.80 | GAA (0.61) | CA2CA9ALDH1A1GAAHTT | |
| SCHEMBL8395286 | 0.79 | MAPT (0.58) | CA2CA9ALDH1A1GAAHTT | |
| SCHEMBL566097 | 0.77 | MAPT (0.53) | CA2CA9ALDH1A1GAAMAPT | |
| SCHEMBL5914229 | 0.77 | RPS6KA2 (0.42) | ALDH1A1GAAMAPTRPS6KA2 | |
| SCHEMBL5697708 | 0.77 | CA2 (0.46) | CA2CA9ALDH1A1GAAHTT | |
| SCHEMBL13192623 | 0.77 | CA2 (0.46) | CA2CA9ALDH1A1GAAMAPT | |
| SCHEMBL7109290 | 0.77 | ALDH1A1 (0.47) | CA2CA9ALDH1A1GAAMAPT | |
| SCHEMBL9172643 | 0.77 | LOXL2 (0.48) | CA2CA9ALDH1A1GAAHTT | |
| SCHEMBL17373965 | 0.77 | CA2 (0.46) | CA2CA9ALDH1A1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | ARRAY BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2023-01-12 | — | — | US | disclosed |
| WO-2005087748-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1576108-A2 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1444982-A1 | The use of purine derivatives as selective kinase inhibitors | MERCKLE GMBH (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-20040014195-A1 | Nitrilases, nucleic acids encoding them and methods for making and using them | DIVERSA CORPORATION (US) | 2004-01-22 | — | — | US | disclosed |
| US-20040002147-A1 | Nitrilases | DIVERSA CORPORATION | 2004-01-01 | — | — | US | disclosed |
| WO-2003097810-A2 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | DIVERSA CORPORATION | 2003-07-03 | — | — | US | disclosed |
| WO-2003000840-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| CN-1097193-A | The preparation of sterilant and intermediate product thereof | RHONE POULENC AGROCHIMIE (FR) | 1995-01-11 | — | — | CN | disclosed |
| EP-0599183-A1 | Manufacturing of pesticides and intermediates | RHONE-POULENC AGROCHIMIE (FR) | 1994-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, MET, AXL | CA2 1496/4885CA9 2613/4885ALDH1A1 2890/4885 |
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | CA2 1938/4885CA9 1222/4885ALDH1A1 2121/4885 |
| US-20040014195-A1 | Nitrilases, nucleic acids encoding them and methods for making and using them | RNGTT, NSUN2, NSUN3 | CA2 882/4885CA9 1247/4885ALDH1A1 1350/4885 |
| US-20040002147-A1 | Nitrilases | RNGTT, DNTT, NOP2 | CA2 674/4885CA9 1080/4885ALDH1A1 953/4885 |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | NIT2, DNPH1, ASNS | CA2 103/4885CA9 165/4885ALDH1A1 1083/4885 |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | CA2 1840/4885CA9 1245/4885ALDH1A1 2323/4885 |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | RET, MERTK, MET | CA2 1938/4885CA9 1222/4885ALDH1A1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.